SAB Biotherapeutics, Inc. SABS
SAB Biotherapeutics, Inc. (Nasdaq: SABS) is an immunology/inflammation drug developer. Its lead program, SAB-142 (fully human anti-thymocyte globulin, Tc-Bovine derived), is in Phase 2 for Stage 3 autoimmune type 1 diabetes (new or recent onset).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SAB-142 - PRISE-hATG (investigator-led registrational Phase 3, Breakthrough T1D grant, company co-funding) | Stage 3 type 1 diabetes, 100 days to 2 years from diagnosis | antibody | Phase 3 |
| SAB-142 - SAFEGUARD (pivotal Phase 2b, Parts A/B/C) | Stage 3 type 1 diabetes | antibody | Phase 2 |
| SAB-142 | Other autoimmune indications (SLE, RA, MS, celiac etc.) | antibody | Pre-clinical |
Recent results and decisions
- Mar 10, 2026positive Additional Phase 1 data: 4 SAB-142 treated T1D patients showed no decrease in C-peptide at Day 120 vs baseline, while the placebo patient declined (exploratory, n=6).
In the T1D cohort (n=6), SAB-142 treated study participants (n=4) showed no decrease in C-peptide levels at Day 120 compared to baseline.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.